2015 American Transplant Congress
Assessing Pre-Vaccination Cytokine Levels to Predict Immunogenicity to Seasonal Trivalent Influenza Vaccine in Solid Organ Transplant Recipients
Multi-Organ Transplant Program, University Health Network, Toronto, Canada.
Background: The immunogenicity of seasonal trivalent influenza vaccine (TIV) in solid organ transplant (SOT) recipients remains suboptimal. We hypothesized that analysis of pre-vaccination T- and…2015 American Transplant Congress
Epidemiology of Early Post Liver Transplant (LT) Infections 2008-12: Time to Reconsider Perioperative Prophylaxis Regimen?
Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Background: The most common pathogens seen in early post LT intraabdominal and bloodstream infection are enterococci, staphylococci and aerobic gram negative bacilli and perioperative prophylaxis…2015 American Transplant Congress
Infectious Complications in ABO Incompatible Kidney Transplantation Recipient According to the Rituximab Dose
BackgroundDesensitization with rituximab and intravenous immunoglobulin improves ABO incompatible (ABOi) kidney transplantation (KT) outcomes. However, infections have been noted in association with rituximab administration. In…2015 American Transplant Congress
Efficacy of Rituximab Sparing Protocol for ABO Incompatible Renal Transplant in Patients With Low Titers
[Introduction]Acute antibody mediated rejection (AMR) has been a major problem in ABO-incompatible kidney transplantation (ABOi-KTx), and currently mycophenolate mofetil and rituximab have been used to…2015 American Transplant Congress
Mesenchymal Stem Cells (MSCs) Transfusion for Desensitization of Positive Lymphocyte Cross Match (LCM) or Panel Reactive Antibodies (PRA) Before Kidney Transplantation – Outcome of 16 Cases
Immunomodulatory function of MSCs may correct positive PRA or LCM in highly-sensitized patients. We evaluate donor specific or 3rd party MSCs transfusion in 16 patients…2015 American Transplant Congress
Desensitization Protocol Including Concomitant Bortezomib and Rituximab Did Not Reduce Calculated PRA Nor Mean MFI Values Among Waitlisted Patients for Deceased Donor Kidney Transplantation
Highly sensitized (HS) patients (pts) seldom have chance to receive deceased donor kidney transplant (DDKT). A desensitization (DES) program including bortezomib was employed to facilitate…2015 American Transplant Congress
Comparison of One-Year Outcomes in High Risk Kidney Transplantation: ABO Incompatible and DSA Positive/CDC-AHG Negative
Back ground: Both donor specific anti-HLA antibody (DSA) and anti-ABO are the major barriers in kidney transplantation. We evaluated the outcomes of desensitization protocols in…2015 American Transplant Congress
Impact of Baseline and Postoperative Isoagglutinin Titer on Clinical Outcomes in ABO-Incompatible Living Donor Kidney Transplantation
Background : ABO-incompatible (ABO-i) kidney transplantation (KT) has expanded in consequence of the development of desensitization protocol. However, the impact of baseline and postoperative isoagglutinin…2015 American Transplant Congress
Interference of Therapeutic Antibodies Used in Desensitization Protocols On Lymphocytotoxicity Crossmatch Results
Background: Therapeutic antibodies used to desensitize patients awaiting a human leukocyte antigen (HLA) or ABO-mismatched graft are suspected to interfere with the lymphocytotoxicity crossmatch (LCT-XM)…2015 American Transplant Congress
Efficacy and Safety of Desensitization Protocol Based On Rituximab Plus MMF in ABO-Incompatible Kidney Transplantation Without Splenectomy
Purpose: An open-label, single arm, multicenter clinical study has been conducted in Japan for prospective examination of the efficacy and safety of desensitization protocol with…
American Transplant Congress abstracts